IADR Abstract Archives
Local Salicylic Acid for Halting Peri-Implantitis Progression in Hyperglycemic Conditions
Objectives: To develop a model of peri-implantitis in a Gottingen minipig model and to evaluate the effect of local application of salicylic acid poly(anhydride-ester) (SAPAE) on peri-implantitis progression in healthy, metabolic syndrome (MS), and type-2 diabetes mellitus (T2DM).
Methods: Eighteen animals were allocated in three groups: (i) control, (ii) MS (diet for obesity induction), and (iii) T2DM (diet + Streptozotocin for T2DM induction). Maxillary and mandible premolars and first molar were extracted. After 3 months, four implants were placed in both jaws of each animal (n=48 implants/systemic condition). After 2 months, peri-implantitis was induced by plaque formation using silk ligatures. Bone loss was investigated by a periodic peri-implant probing protocol. SAPAE polymer was mixed with mineral oil (3.75mg/microL) and topically applied biweekly for up to 60 days to halt peri-implantitis progression. Periodontal probing was also used to assess pocket depth over time. Histomorphologic analysis also performed.
Results: The adopted protocol resulted in the onset of peri-implantitis, with evident signs of plaque formation and inflammation such as reduced redness, swelling, and bleeding on probing. A similar rate of bone loss was observed for maxillary and mandible implants, and healthy minipigs took twice as long to reach the same level of bone loss than MS and T2DM minipigs (~3.0 mm). In a qualitative analysis, SAPAE therapy revealed decreased levels of inflammation in normoglycemic, MS, and T2DM groups. The periodic application of SAPAE around implants reduced the progression of peri-implantitis, and lower levels of bone loss relative to control groups were observed; statistically significant after ~50 days of therapy for healthy subjects and 10-20 days for metabolically compromised subjects, with approximately 30% reduction in the bone loss.
Conclusions: MS and T2DM conditions presented a faster onset and progression of peri-implant pocket depth. SAPAE treatment reduced peri-implantitis progression in health, MS and T2DM groups.
Methods: Eighteen animals were allocated in three groups: (i) control, (ii) MS (diet for obesity induction), and (iii) T2DM (diet + Streptozotocin for T2DM induction). Maxillary and mandible premolars and first molar were extracted. After 3 months, four implants were placed in both jaws of each animal (n=48 implants/systemic condition). After 2 months, peri-implantitis was induced by plaque formation using silk ligatures. Bone loss was investigated by a periodic peri-implant probing protocol. SAPAE polymer was mixed with mineral oil (3.75mg/microL) and topically applied biweekly for up to 60 days to halt peri-implantitis progression. Periodontal probing was also used to assess pocket depth over time. Histomorphologic analysis also performed.
Results: The adopted protocol resulted in the onset of peri-implantitis, with evident signs of plaque formation and inflammation such as reduced redness, swelling, and bleeding on probing. A similar rate of bone loss was observed for maxillary and mandible implants, and healthy minipigs took twice as long to reach the same level of bone loss than MS and T2DM minipigs (~3.0 mm). In a qualitative analysis, SAPAE therapy revealed decreased levels of inflammation in normoglycemic, MS, and T2DM groups. The periodic application of SAPAE around implants reduced the progression of peri-implantitis, and lower levels of bone loss relative to control groups were observed; statistically significant after ~50 days of therapy for healthy subjects and 10-20 days for metabolically compromised subjects, with approximately 30% reduction in the bone loss.
Conclusions: MS and T2DM conditions presented a faster onset and progression of peri-implant pocket depth. SAPAE treatment reduced peri-implantitis progression in health, MS and T2DM groups.